featured
2020 Top Stories in Oncology: HIF2α Blockade Provides Significant Clinical Benefit in Patients With VHL Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Jonasch E, Donskov F, Iliopoulos O, et al. Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease–associated renal cell carcinoma. J Clin Oncol. 2020;38(suppl 15):5003.
- Srinivasan R, Donskov F, Iliopoulos O, et al. Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): update on RCC and non-RCC disease. Ann Oncol. 2020;31(suppl 4):S1142-S1215.
Disclosure statements are available on the authors' profiles: